SFA Therapeutics Harnesses Power Of Bacterial Metabolites To Treat Inflammatory Disease
Emerging Company Profile: The US biotech is advancing its lead candidate into a Phase Ib psoriasis trial as it works to validate its bacterial metabolite-based drug platform, which exemplifies a new generation of microbiome technology.
You may also be interested in...
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.
Recent executive moves in the industry include C-suite changes at Fresh Tracks Therapeutics and Protara Therapeutics. Meanwhile, new directors were appointed at Grey Wolf Therapeutics and BioSenic.
The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.